<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thromboangiitis obliterans (Buerger disease)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thromboangiitis obliterans (Buerger disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thromboangiitis obliterans (Buerger disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey W Olin, DO</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Creager, MD, FAHA, FACC, MSVM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thromboangiitis obliterans (TAO), also called Buerger disease, is a nonatherosclerotic, segmental, inflammatory disease that most commonly affects the small to medium-sized arteries and veins of the extremities (upper and lower) [<a href="#rid1">1-3</a>]. TAO is characterized by highly cellular and inflammatory occlusive thrombus with relative sparing of the blood vessel wall [<a href="#rid4">4</a>]. Patients are young smokers who present with distal extremity ischemia, ischemic digit ulcers, or digit gangrene [<a href="#rid5">5</a>]. The disease is strongly associated with the use of tobacco products, and smoking cessation is important to decrease the risk for amputation. Cannabis arteritis is clinically and pathologically indistinguishable from TAO but occurs less commonly compared with tobacco-related TAO. </p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of TAO are reviewed here.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>TAO is observed worldwide but is more common in countries where tobacco is heavily used, especially among people who make homemade cigarettes from raw tobacco (sometimes mixed with cannabis) [<a href="#rid6">6</a>]. As such, TAO is most prevalent in the Mediterranean, Middle East, and Asia [<a href="#rid7">7,8</a>]. In other parts of the world, among patients with arterial occlusive disease, the prevalence varies widely, ranging from 0.5 to 5.6 percent in Western Europe, 15 to 66 percent in Korea and Japan, and as high as 45 to 63 percent in India [<a href="#rid9">9-11</a>]. </p><p>Because of a decline in the rate of cigarette smoking and the use of stricter criteria for the diagnosis, the prevalence of TAO has declined in North America and Western Europe [<a href="#rid2">2,8,12</a>]. Evidence for the decline in the prevalence of TAO comes from a study that identified patients with TAO between 2015 and 2018 where hospital admissions for TAO represented 0.3 percent of all peripheral vascular disease admissions. There was a dramatic decrease in smokers from 2005 to 2019 (21 versus 14 percent of the population) [<a href="#rid13">13</a>]. Whether vaping (aerosol inhalation that includes nicotine or other substances) will affect the incidence of TAO is unknown. (See  <a class="medical medical_review" href="/d/html/98400.html" rel="external">"Vaping and e-cigarettes", section on 'Adverse health effects'</a>.)</p><p>Males are more commonly affected than females. Of patients diagnosed with TAO, 70 to 91 percent are male and 11 to 30 percent are female [<a href="#rid14">14</a>]. However, there are reports of increasing prevalence of disease in females, possibly due to the increasing use of cigarettes among females [<a href="#rid5">5,12,14-20</a>]. The majority of patients present before the age of 45. However, a report from Japan suggests that the epidemiology may be changing, with a higher percentage of patients over the age of 50 on initial diagnosis [<a href="#rid10">10</a>]. It appears the clinical spectrum of Buerger disease has changed over the last 40 years [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The use of tobacco is essential for the initiation and progression of TAO [<a href="#rid22">22-24</a>]. There has never been a well-documented case of TAO in a patient who was proven not to be using tobacco or cannabis in some form (ie, as confirmed by measuring urine nicotine or cotinine levels and toxicology screen). </p><p>Patients are generally heavy cigarette smokers. In one study, patients diagnosed with TAO smoked an average of 23 years [<a href="#rid24">24</a>]. TAO has also been reported in cigar smokers, marijuana users (cannabis arteritis), and those who use smokeless tobacco such as chewing tobacco and snuff [<a href="#rid4">4,5,15,25-29</a>]. </p><p>Chronic anaerobic periodontal infection may also play a role in the development of TAO [<a href="#rid30">30-32</a>]. Nearly two thirds of patients with TAO have severe periodontal disease. In one study, DNA fragments associated with anaerobic bacteria were found within both the arterial lesions and oral cavities of patients with TAO [<a href="#rid31">31</a>]. However, the prevalence of periodontal disease in smokers without TAO is similarly high, and thus the association may be confounded. </p><p class="headingAnchor" id="H514794264"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>TAO is a segmental inflammatory, nonatherosclerotic, occlusive vascular disease that affects the small and medium-sized arteries and veins of the upper and lower extremities. Despite its strong association with tobacco exposure, the general pathophysiology of the disease is still not well known. </p><p>Histologically, the condition is distinguished from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus with relative sparing of the vessel wall and, more specifically, sparing of the internal elastic lamina [<a href="#rid33">33,34</a>]. Although the disease was recognized and the pathology described over 100 years ago, its pathogenesis remains poorly understood with little progress in understanding the pathogenesis or in the treatment of TAO [<a href="#rid35">35,36</a>]. </p><p>Three pathologic phases are described (<a class="graphic graphic_picture graphicRef59478" href="/d/graphic/59478.html" rel="external">picture 1</a>) [<a href="#rid34">34,37</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>In the acute phase, inflammatory thrombi develop in the arteries and veins, typically of the distal extremities. The thrombus is occlusive, and polymorphonuclear leukocytes, microabscesses, and multinucleated giant cells may be present, but there is no evidence of fibrinoid necrosis [<a href="#rid33">33,34</a>]. Although the external elastic lamina may show some disruption, the internal elastic lamina is intact. (See <a class="local">'Biopsy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The intermediate (subacute) phase is characterized by progressive organization of the thrombus in the small to medium-sized arteries and veins. A prominent inflammatory infiltrate is still present within the thrombus but is less in the vessel wall.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the chronic phase, inflammation is no longer present and only organized thrombus and vascular fibrosis remain. The pathological appearance in the chronic phase is indistinguishable from all other types of occlusive arterial disease.</p><p></p><p>Although smoking tobacco is central to the initiation, continuation, and recurrence of disease, the specific role of smoking in the pathogenesis of thromboangiitis is unknown. It is postulated that smoking may cause a delayed type of hypersensitivity or toxic angiitis. Immunohistochemical analyses indicate an inflammatory and immunologic pathogenesis [<a href="#rid23">23,38-43</a>]. An increased production of cytokines and a role of notch signal activation may contribute to the inflammatory response observed in patients with Buerger disease [<a href="#rid44">44,45</a>]. </p><p>Endothelial dysfunction may also be involved in the pathogenesis of TAO [<a href="#rid38">38,46-48</a>]. High titers of antiendothelial antibodies have been detected [<a href="#rid46">46</a>]. Vascular invasion of the tunica intima and also the tunica media is clearly demonstrated in affected vessels using endothelial cell-specific antigens. There also appears to be impaired endothelium-dependent vasodilation in angiographically normal appearing limbs of patients diagnosed with TAO [<a href="#rid49">49</a>]. Abnormalities in endothelin may also play a role [<a href="#rid50">50</a>]. </p><p>Prothrombotic factors may also play a role in the pathogenesis of TAO. The presence of anticardiolipin antibodies has been reported to be associated with an increased risk and severity of disease [<a href="#rid38">38,51,52</a>]. </p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>TAO typically presents in young smokers less than 45 years of age.<strong> </strong>Vascular involvement in TAO usually begins with the distal arteries and veins, followed by more proximal arterial occlusive disease. Two or more extremities are usually involved [<a href="#rid4">4,19</a>]. A seasonal variation has also been reported with patients more likely to present in the winter [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H3165421023"><span class="h2">Presentations</span></p><p class="headingAnchor" id="H2839958514"><span class="h3">Superficial thrombophlebitis</span><span class="headingEndMark"> — </span>A migratory superficial thrombophlebitis can occur as a very early disease manifestation even before other symptoms and signs (<a class="graphic graphic_picture graphicRef113320" href="/d/graphic/113320.html" rel="external">picture 2</a>), such as extremity pain or digital ischemia, become clinically evident. The phlebitis consists of tender nodules that follow a venous distribution and frequently parallels arterial disease activity [<a href="#rid15">15,53</a>]. </p><p>When superficial nodules are present, they should be biopsied to establish a histologic diagnosis, since these lesions are most likely to show the acute phase of TAO. (See <a class="local">'Biopsy'</a> below.)</p><p>The presence of superficial phlebitis distinguishes this disorder from other occlusive vascular diseases, though phlebitis may also be observed in Behçet syndrome. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3185148474"><span class="h3">Cold sensitivity/Raynaud phenomenon</span><span class="headingEndMark"> — </span>Another early manifestation is cold sensitivity with initial presentations of TAO more common in winter months. Secondary Raynaud phenomenon occurs in more than 40 percent of patients and may be asymmetric. The frequency of Raynaud phenomenon may depend upon the population studied [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a>.)</p><p>Cold sensitivity may be due to markedly increased muscle sympathetic nerve activity, which has been demonstrated in patients with TAO compared with control subjects, or it can be related to ischemia [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H3226403606"><span class="h3">Digital ischemia</span><span class="headingEndMark"> — </span>Digital (toe, finger) ischemia is the most common presentation of TAO. Patients usually note pain, and subsequently the extremities, particularly the digits, may be characterized by either rubor or cyanosis. This discoloration has been termed "Buerger's color." Ischemia can progress to ulcerations in the upper or lower extremity (<a class="graphic graphic_picture graphicRef113320" href="/d/graphic/113320.html" rel="external">picture 2</a>) with accompanying ischemic pain or gangrene of the fingers or toes (<a class="graphic graphic_picture graphicRef80866" href="/d/graphic/80866.html" rel="external">picture 3</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>In one review of 112 patients, 66 percent had ischemic ulcerations at the time of presentation [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower extremity ulcers occurred in 46 percent, upper extremity ulcers in 28 percent, and ulcers in both upper and lower extremities in 26 percent in one series [<a href="#rid55">55</a>]. In another review, combined upper and lower extremity disease occurred in 20 percent of patients [<a href="#rid20">20</a>]. In a series of 323 patients who presented with upper extremity ischemia from 2000 to 2016, TAO was the cause in 30 (9.3 percent [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another group reported that two limbs were affected in 16 percent of patients, three limbs in 41 percent, and all four limbs in 43 percent [<a href="#rid14">14</a>]. As a general rule, TAO always involves more than one limb.</p><p></p><p>As the disease progresses, it may involve the more proximal arteries. While unusual, when large artery involvement is present, it rarely occurs in the absence of small vessel occlusive disease [<a href="#rid19">19</a>]. In one retrospective review, the outcomes of 30 of 83 patients with large artery TAO (36.1 percent) were compared with 53 of 83 patients with small artery TAO (63.9 percent). The symptoms and signs, and the proportion of patients with tissue loss was significantly higher for the large compared with small artery group (13.3 versus 0 percent) [<a href="#rid57">57</a>]. While the authors stated they followed strict criteria for the diagnosis of TAO, it is unclear if those with large vessel involvement had histopathologic proof of TAO as suggested in many of the published criteria [<a href="#rid58">58</a>]. </p><p>If vessels proximal to the wrist or ankle become involved, the patient may complain of claudication of the feet, calves, thighs, or pain in the hands or arms with activity [<a href="#rid4">4</a>]. Symptoms of claudication due to TAO may be indistinguishable from other vascular occlusive diseases. Foot claudication is often mistaken for an orthopedic problem. (See  <a class="medical medical_review" href="/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.) </p><p class="headingAnchor" id="H2666119351"><span class="h3">Other organ ischemia</span><span class="headingEndMark"> — </span>Although TAO most commonly affects the small and medium arteries of the extremities, pathologic findings have been reported in cerebral, coronary, internal thoracic, renal, and mesenteric arteries [<a href="#rid59">59-61</a>]. Symptoms from intestinal or multiorgan involvement are rare but have been reported [<a href="#rid62">62,63</a>]. Involvement of large vessels, such as the aorta and iliac arteries, is rare; it was noted in just one report [<a href="#rid57">57</a>]; occlusive disease of these vessels is more likely to be due to atherosclerotic arterial occlusive disease [<a href="#rid19">19</a>]. With patients with TAO living longer, it is not uncommon to see features of both TAO and atherosclerosis.</p><p class="headingAnchor" id="H3884959017"><span class="h3">Joint complaints</span><span class="headingEndMark"> — </span>In a minority of patients, joint complaints may be the first indication of clinical disease. In one study, arthralgias and arthritis were reported in 12.5 percent of patients, typically in the preocclusive phase [<a href="#rid53">53</a>]. The most commonly affected joints were the wrists and knees. The duration of joint symptoms prior to the digital ischemia can be months to years. The joint manifestations of TAO do not lead to erosive arthritis and are frequently episodic, generally resolving within two weeks.</p><p class="headingAnchor" id="H87000089"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>All patients should have a thorough history and physical including a detailed vascular examination. The extremities should be inspected for superficial venous nodules and cords. The hands and feet examined for evidence of ischemia. Neurologic examination may document peripheral nerve involvement with sensory abnormalities in up to 70 percent of patients [<a href="#rid4">4</a>]. </p><p>The physical examination alone cannot distinguish arterial occlusive disease due to TAO from other etiologies (<a class="graphic graphic_table graphicRef68663" href="/d/graphic/68663.html" rel="external">table 1</a>). Given that smoking is a common risk factor, it is not surprising that atherosclerotic peripheral artery disease (PAD) may be superimposed, particularly in older patients with TAO.</p><p>For patients with lower extremity signs and symptoms, an ankle-brachial index (ABI) should be performed. Similarly, a wrist-brachial index (WBI) can be performed in the upper extremity. (See  <a class="medical medical_review" href="/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'</a> and  <a class="medical medical_review" href="/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Wrist-brachial index'</a>.)</p><p>A normal ABI or WBI does not exclude TAO, because disease may be limited to the distal vasculature. Thus, digit studies (pressures, waveforms) should be obtained for all patients in whom the diagnosis of TAO is considered. (See <a class="local">'Vascular testing'</a> below.)</p><p>An Allen test should also be performed (<a class="graphic graphic_picture graphicRef120776" href="/d/graphic/120776.html" rel="external">picture 4</a>). A positive Allen test means there is occlusion of the radial or ulnar artery distal to the wrist. A positive Allen test at the wrist in a young smoker with lower extremity digital ischemia is suggestive of TAO (<a class="graphic graphic_picture graphicRef79685" href="/d/graphic/79685.html" rel="external">picture 5</a>) [<a href="#rid2">2</a>]. Methods for performing the Allen test at the hand and foot, and adjunctive use of duplex ultrasound, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1648.html" rel="external">"Arterial blood gases", section on 'Ensure collateral circulation'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>There are no specific laboratory tests to diagnose TAO. The purpose of laboratory studies is to exclude other entities that cause occlusive vascular disease (<a class="graphic graphic_table graphicRef68663" href="/d/graphic/68663.html" rel="external">table 1</a>), such as diabetes, the vasculitides (eg, lupus, mixed connective tissue disease, scleroderma, limited scleroderma [formally called CREST; calcinosis, Raynaud, esophageal dysmotility, sclerodactyly, telangiectasias] syndrome), and thrombophilias. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Patients should undergo a complete blood count with differential, a chemistry panel including fasting blood sugar, liver enzymes, renal function, urinalysis, and a serologic profile that includes the following [<a href="#rid2">2,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute phase reactants – Westergren erythrocyte sedimentation rate (ESR), C-reactive protein (CRP). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunologic panel – Antinuclear antibody (ANA), rheumatoid factor (RF), complement measurements, cryoglobulins,<strong> </strong>anticentromere antibody, and SCL70 (markers for scleroderma and limited scleroderma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete hypercoagulability screen – Coagulation tests, antiphospholipid antibodies (anticardiolipin antibodies, beta 2 glycoprotein, antiserine antibodies, and lupus anticoagulant) protein C, protein S, antithrombin, factor V Leiden, and prothrombin gene mutation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxicology panel – Cocaine, amphetamines [<a href="#rid64">64</a>], cannabis.</p><p></p><p>These tests usually are normal or negative in patients with TAO. However, anticardiolipin antibodies may be present in some patients with TAO [<a href="#rid51">51,65</a>]. For patients who deny smoking or using tobacco in any form (cigarettes, cigars, pipe, vape, chew, snuff) who present with findings suggestive of TAO, a urine sample for nicotine and cotinine should be obtained. In addition, cannabis arteritis, which is clinically and pathologically indistinguishable from TAO, also requires a positive urine screen for cannabis to make the diagnosis. </p><p class="headingAnchor" id="H86999828"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>TAO is a predominantly clinical diagnosis that should be suspected in young patients who smoke and who present with ischemia of the hands and/or feet. However, the diagnosis of TAO may be a diagnosis of exclusion after ruling out other more common entities that may produce similar clinical symptoms. Biopsy provides a definitive diagnosis, although pathological evidence of acute TAO is most likely to be present when an area of superficial thrombophlebitis or subcutaneous nodules are biopsied. Some clinicians use a scoring system to diagnose TAO based upon clinical, angiographic, histopathological, and exclusionary criteria [<a href="#rid5">5,66</a>].</p><p class="headingAnchor" id="H86999781"><span class="h2">Clinical criteria</span><span class="headingEndMark"> — </span>A clinical diagnosis can be established without the need for biopsy using the following commonly used criteria [<a href="#rid67">67-70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age less than 50 years [<a href="#rid69">69,70</a>] (45 years in earlier studies [<a href="#rid68">68</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current or recent history of tobacco use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distal extremity ischemia (objectively noted on vascular testing) (see <a class="local">'Physical examination'</a> above and <a class="local">'Vascular testing'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typical arteriographic findings of TAO (see <a class="local">'Vascular imaging'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (<a class="graphic graphic_table graphicRef68663" href="/d/graphic/68663.html" rel="external">table 1</a>) (see <a class="local">'Laboratory studies'</a> above)</p><p></p><p>Other criteria have been cited in the literature but are less commonly used [<a href="#rid66">66,71</a>]. </p><p class="headingAnchor" id="H461453879"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsy is rarely needed but is the only means to establish a definitive diagnosis. Patients in whom there is suspicion for TAO who have subcutaneous nodules or superficial thrombophlebitis should undergo biopsy. Biopsy of an involved superficial vein that demonstrates acute thrombophlebitis and the characteristic acute phase lesion (<a class="graphic graphic_picture graphicRef59478" href="/d/graphic/59478.html" rel="external">picture 1</a>) confirms the diagnosis. (See <a class="local">'Pathophysiology'</a> above.)</p><p>Biopsy is also suggested if the patient presents with some clinical findings of TAO but unusual characteristics such as large artery involvement [<a href="#rid57">57,58</a>], age &gt;50 years, diabetes, positive antinuclear antibodies, or the presence of elevated anticardiolipin antibodies. Patients with antiphospholipid syndrome exhibit thrombus without inflammation, ruling out a diagnosis of TAO [<a href="#rid51">51</a>]. </p><p>If there are no nodules or superficial thrombophlebitis and the patient fulfills the above criteria, a biopsy of an artery can be done, or examination of the vein or arteries in an amputated digit or limb may provide a diagnosis; however, this is rarely done.</p><p class="headingAnchor" id="H32623830"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>TAO is differentiated from other entities that cause vascular occlusive disease (<a class="graphic graphic_table graphicRef68663" href="/d/graphic/68663.html" rel="external">table 1</a>). In a series of 323 patients who presented with upper extremity ischemia from 2000 to 2016, TAO was the cause in 30 (9.3 percent). Other common causes were cardioembolic (18.3 percent), systemic sclerosis (16.1 percent), idiopathic (11.7 percent), and iatrogenic (9.3 percent) [<a href="#rid56">56</a>]. The most common of which are presented briefly below (<a class="graphic graphic_table graphicRef128128" href="/d/graphic/128128.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef58846" href="/d/graphic/58846.html" rel="external">table 3</a>) and discussed in further detail in the linked topics: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral artery disease (PAD)</strong> – The distal nature of TAO and involvement of both the lower and upper extremities helps to distinguish TAO from PAD. Other risk factors for peripheral artery disease, such as hypertension or hypercholesterolemia, may be absent. In the absence of a histologic diagnosis of the acute phase lesion, a diagnosis of diabetes mellitus excludes TAO. (See  <a class="medical medical_review" href="/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboembolic disease</strong> – Patients with TAO will not have a proximal source for embolism (cardiac, aneurysm, atherosclerotic plaque) or laboratory evidence of a thrombophilia, though anticardiolipin antibodies may be present. (See  <a class="medical medical_review" href="/d/html/14938.html" rel="external">"Embolism to the upper extremities"</a> and  <a class="medical medical_review" href="/d/html/112120.html" rel="external">"Embolism to the lower extremities"</a> and  <a class="medical medical_review" href="/d/html/8197.html" rel="external">"Thromboembolism from aortic plaque"</a> and  <a class="medical medical_review" href="/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis</strong> – Although distal vessel involvement causes distal ischemia, many types of vasculitides and serologic markers are negative in TAO. (See  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a> and  <a class="medical medical_review" href="/d/html/8224.html" rel="external">"Overview of the management of vasculitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repetitive trauma</strong> – These patients have an occupational history (eg, jackhammer operator or other vibratory tools) explaining the mechanism of small vessel disease. The severity of disease depends on degree of vibration, total hours of use, grip force, handle size, and the combined association with other conditions that cause Raynaud phenomenon [<a href="#rid72">72</a>]. Chronic trauma may lead to aneurysm of the distal ulnar artery (ie, hypothenar hammer syndrome), which can then embolize to the hand. It is very important to take a detailed occupational history in every patient with digital ischemia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication effects </strong>(eg, amphetamines or cocaine). (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="headingAnchor" id="H526145984"><span class="h1">FURTHER EVALUATION</span></p><p class="headingAnchor" id="H2629955098"><span class="h2">Vascular testing</span><span class="headingEndMark"> — </span>Patients suspected of having arterial occlusive disease due to TAO should be referred to the vascular laboratory to confirm abnormal ankle-brachial index (ABI) or wrist-brachial index (WBI) findings and for additional studies, as indicated, to identify the level of obstruction (eg, segmental pressures, pulse volume recordings, digit pressures). </p><p>A normal ABI or WBI does not exclude TAO, because disease may be limited to the distal vasculature. The distal circulation can be evaluated using digit plethysmography, which may demonstrate one or more flattened digit waveforms supporting the diagnosis. Toe or finger pressures can also be obtained. However, these tests cannot distinguish disease due to TAO from other causes of small vessel occlusive disease that affect the digital arteries (eg, scleroderma). (See  <a class="medical medical_review" href="/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Digit waveforms'</a> and  <a class="medical medical_review" href="/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Toe-brachial index'</a>.)</p><p class="headingAnchor" id="H2275125761"><span class="h2">Vascular imaging</span><span class="headingEndMark"> — </span>Clinical examination along with testing to exclude other conditions usually suffices to establish the diagnosis [<a href="#rid14">14,69,70,73</a>]. However, for patients with arterial disease established on noninvasive vascular studies who have clinical symptoms and signs consistent with but not definitive for TAO, catheter-based arteriography may be obtained to look for features typical for TAO and identify the extent of disease [<a href="#rid74">74</a>]. </p><p>Although gadolinium-enhanced magnetic resonance (MR) angiography or multidetector computed tomographic (CT) angiography can be used to image the vasculature, these modalities may still not provide sufficient spatial resolution to provide adequate anatomic detail of the vasculature of the hands and feet. (See  <a class="medical medical_review" href="/d/html/101673.html" rel="external">"Advanced vascular imaging for lower extremity peripheral artery disease", section on 'Magnetic resonance angiography'</a>.)</p><p>Because of the high prevalence of disease in multiple limbs, we image both of the upper and lower extremities, and the entire aorta (thoracic and abdominal), even in patients who present with clinical involvement of only one extremity. Angiographic abnormalities consistent with TAO can also be seen in limbs that are not yet clinically involved. </p><p>Arteriographic features suggestive of TAO include (<a class="graphic graphic_diagnosticimage graphicRef64278" href="/d/graphic/64278.html" rel="external">image 1</a>) [<a href="#rid2">2,73-75</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of atherosclerosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No source for thromboembolism (eg, aneurysmal disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of small and medium-sized vessels such as the plantar, tibial, peroneal, palmar, radial, and ulnar arteries</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Segmental occlusion with diseased segments interspersed between normal-appearing segments </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Collateralization around areas of occlusion (ie, corkscrew collaterals) (<a class="graphic graphic_diagnosticimage graphicRef64278" href="/d/graphic/64278.html" rel="external">image 1</a>)</p><p></p><p>Although the findings given above are suggestive, none are pathognomonic for TAO, since they may be found in patients with other causes of small vessel occlusive disease. Several studies using duplex ultrasonography have demonstrated corkscrew collaterals [<a href="#rid76">76,77</a>]. </p><p>The arteriographic findings in patients with cocaine, amphetamine, or cannabis ingestion, including the presence of corkscrew collaterals, may mimic those of TAO [<a href="#rid27">27-29,78,79</a>]. Therefore, in patients who present with manifestations of TAO, it is advisable to obtain a toxicology screen for cocaine, amphetamine, and cannabis. (See <a class="local">'Laboratory studies'</a> above.)</p><p>A cardiac source or other source of embolism should also be ruled out. (See  <a class="medical medical_review" href="/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism"</a> and  <a class="medical medical_review" href="/d/html/14938.html" rel="external">"Embolism to the upper extremities"</a> and  <a class="medical medical_review" href="/d/html/112120.html" rel="external">"Embolism to the lower extremities"</a>.) </p><p>If evaluation suggests the presence of concomitant ischemic heart disease that requires subsequent cardiac catheterization, then consideration should be given to performing arteriography of the internal thoracic arteries. As noted above, involvement of these arteries may occasionally occur in TAO, and planning for coronary bypass surgery is facilitated if their patency is assessed prior to heart surgery.</p><p class="headingAnchor" id="H11"><span class="h1">MEDICAL MANAGEMENT</span><span class="headingEndMark"> — </span>There has been no significant change in the way a patient with TAO is medically treated, with only incremental new information published since the 1960s [<a href="#rid33">33,36,80,81</a>]. Based on a handful of small observational studies, the most effective way to "treat" TAO is to convince the patient that complete abstinence of tobacco and cannabis use will substantially lessen the likelihood of amputation [<a href="#rid15">15</a>]. Although a number of other therapies have been investigated, these should be considered palliative. </p><p>Digital ulcerations are managed as with other ischemic wounds, including debridement and an appropriate dressing. Negative pressure wound therapy is becoming popular for the management of open wounds and has also been used in the management of open wounds associated with TAO [<a href="#rid82">82</a>]. General considerations for the clinical assessment and management of chronic ulcers are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15079.html" rel="external">"Clinical assessment of chronic wounds"</a> and  <a class="medical medical_review" href="/d/html/2881.html" rel="external">"Negative pressure wound therapy"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>In addition to other benefits associated with smoking cessation, we recommend that patients discontinue cigarette smoking and the use of any other tobacco products, as well as to abstain from cannabis in any form. Smoking cessation is the only effective strategy for reducing symptoms in patients diagnosed with TAO, and in virtually every study published, it decreases the risk for major amputation. In a small retrospective review, all 38 patients were asked to stop smoking 15 days before an interventional procedure [<a href="#rid83">83</a>]. In the 24 individuals who were able to stop smoking, the technical success rate 96 percent compared with 65 percent for the eight patients who did not stop smoking. The outcome at one month was also improved in those that stopped smoking. (See <a class="local">'Outcomes'</a> below.)</p><p>Complete abstinence from tobacco products is the only means by which to halt the progression of TAO [<a href="#rid4">4</a>]. The disease may be activated by smoking as little as one or two cigarettes a day. Transdermal nicotine patches and nicotine chewing gum should also be avoided because they may also keep the disease active; however, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> can be used as aids to smoking cessation. Inpatient nicotine dependence treatment is an alternative for recidivist smokers [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>While urine assays are used frequently in research studies to verify smoking cessation, they are not routinely obtained in the general clinical setting. However, since the correlation between smoking and disease activity is so strong, measurement of urinary nicotine and cotinine (a byproduct of nicotine) should be performed if the disease is active despite patient claims of tobacco cessation [<a href="#rid85">85</a>]. </p><p>Patients can be reassured that if they are able to discontinue tobacco use, the disease will remit and the need for amputation will be low. However, patients may continue to experience intermittent claudication or Raynaud phenomenon.</p><p>Unfortunately, only about half of patients are able to maintain smoking cessation long term [<a href="#rid4">4,15,81,86</a>]. In one series of 110 patients, only 41 (37 percent) were able to discontinue smoking [<a href="#rid86">86</a>]. In the author's series, among 120 patients with Buerger disease, 43 percent had discontinued cigarette smoking after an average of 7.6 years of follow-up [<a href="#rid4">4,15,68</a>]. Overall, 94 percent of those who quit smoking avoided amputation. If there was no gangrene when the patient discontinued smoking, amputation did not occur. Among the 43 percent of those who continued smoking, one or more amputations was required. In another series, among 48 patients who experienced amputation, 89.6 percent were current smokers [<a href="#rid81">81</a>]. (See <a class="local">'Outcomes'</a> below.) </p><p class="headingAnchor" id="H2356692848"><span class="h2">Intermittent pneumatic compression</span><span class="headingEndMark"> — </span>While there are limited data, specifically in TAO, intermittent pneumatic compression (IPC) is effective for the treatment of small vessel occlusive disease of many etiologies. IPC is an option for patients with painful ulceration when there is no viable revascularization option. (See  <a class="medical medical_review" href="/d/html/94161.html" rel="external">"Investigational therapies for treating symptoms of lower extremity peripheral artery disease", section on 'Pneumatic compression'</a>.)</p><p>Application of IPC to the calf augments popliteal artery flow through a decrease in peripheral arterial resistance. Peak systolic and end diastolic flow velocities are increased on Doppler ultrasound [<a href="#rid87">87</a>]. In one study, complete healing of ischemic ulcers occurred in patients with small vessel occlusive diseases such as scleroderma, CREST, and TAO [<a href="#rid88">88</a>]. While effective, it often takes months to achieve ulcer healing and patients must use the pump for about six hours a day, but pain may decrease even before complete ulcer healing occurs. </p><p class="headingAnchor" id="H3475698895"><span class="h2">Vasodilators</span><span class="headingEndMark"> — </span>Vasodilators can be used in patients with TAO to help alleviate symptoms. Pharmacologic agents that have been predominantly investigated in TAO include prostacyclin analogues and phosphodiesterase inhibitors. Other vasodilators such as calcium channel antagonists, alpha-adrenergic receptor antagonists, and transdermal nitrates may be helpful in patients who experience vasospasm, but these have not been prospectively studied for the treatment of TAO. </p><p class="headingAnchor" id="H3102745555"><span class="h3">Intravenous prostaglandins</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8895" href="/d/drug information/8895.html" rel="external">Iloprost</a>, a prostacyclin analog, is the best studied vasodilator and is used frequently in European and Asian countries. Intravenous iloprost is used since oral prostaglandin does not appear to be effective for healing lesions [<a href="#rid89">89</a>]. While there are randomized data to suggest that intravenous iloprost may be helpful [<a href="#rid80">80,90-92</a>], its practicality is limited because in the clinical trials, the patients received a six-hour infusion every day for 28 days and were hospitalized the entire time. Thus, we do not routinely use intravenous iloprost to treat patients with TAO. The main benefit of iloprost may be in helping patients with severe ischemia get through the period of initial smoking cessation. (See  <a class="medical medical_review" href="/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia", section on 'Intravenous prostaglandins'</a>.)</p><p class="headingAnchor" id="H1064754115"><span class="h3">Phosphodiesterase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">Cilostazol</a>, a phosphodiesterase type 3 inhibitor with vasodilator properties, may become useful in the management of TAO [<a href="#rid93">93</a>]. Cilostazol is often used in the treatment of atherosclerotic peripheral artery disease. In one experimental study, cilostazol reduced the expression of inflammatory mediators in the plasma of patients with TAO [<a href="#rid94">94</a>]. Cilostazol has also improved healing of ischemic ulcerations in patients who were not candidates for revascularization, though not specifically in the TAO population [<a href="#rid95">95</a>]. Prospective trials are needed to establish clinical efficacy in patients with TAO. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Cilostazol'</a>.)</p><p><a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">Sildenafil</a> and <a class="drug drug_general" data-topicid="10108" href="/d/drug information/10108.html" rel="external">tadalafil</a>, which are phosphodiesterase type 5 inhibitors, are other potential options in this drug class that have been shown to help decrease the frequency and severity of Raynaud phenomenon. However, there are no data on the use of these agents in TAO. (See  <a class="medical medical_review" href="/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management", section on 'Phosphodiesterase type 5 inhibitor'</a>.)</p><p class="headingAnchor" id="H4092708393"><span class="h3">Calcium channel blockers</span><span class="headingEndMark"> — </span>When significant vasospasm as a manifestation of secondary Raynaud phenomenon is present in patients with TAO, dihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>) should be used [<a href="#rid4">4,96</a>]. (See <a class="local">'Cold sensitivity/Raynaud phenomenon'</a> above and  <a class="medical medical_review" href="/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management", section on 'Calcium channel blocker'</a>.)</p><p class="headingAnchor" id="H268457277"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Cell-based therapies or gene therapy can be tried and may be an alternative for treating ischemic manifestations of TAO [<a href="#rid55">55,97</a>]. Another therapy under investigation is treatment with <a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">bosentan</a>, which is an endothelin inhibitor [<a href="#rid50">50,98</a>]. Other investigational therapies used to treat atherosclerotic occlusive disease, most of which have not led to significant improvements in patients with TAO, are discussed separately. (See  <a class="medical medical_review" href="/d/html/94161.html" rel="external">"Investigational therapies for treating symptoms of lower extremity peripheral artery disease", section on 'Stem cell therapy'</a> and  <a class="medical medical_review" href="/d/html/94161.html" rel="external">"Investigational therapies for treating symptoms of lower extremity peripheral artery disease", section on 'Therapeutic angiogenesis'</a>.)</p><p>Cell-based therapies (eg, autologous bone marrow mononuclear cell implantation, therapeutic angiogenesis using growth factors, and stimulation of autologous bone marrow) have been used with some degree of short-term success in patients with chronic limb-threatening ischemia, but longer-term studies are needed [<a href="#rid99">99</a>]. A confounding factor for many of these studies is that many of the patients concurrently ceased smoking. </p><p>The therapeutic angiogenesis by cell transplantation (TACT) trial, which included patients with TAO, randomly assigned patients to autologous bone marrow mononuclear cell injection versus placebo [<a href="#rid100">100</a>]. Significant improvements in leg pain scale, ulcer size, and pain-free walking distance were maintained at two years after therapy. Similar short-term improvements are reported in other small nonrandomized studies [<a href="#rid58">58,101-104</a>]. Most studies have not reported significant adverse events to angiogenic therapy; however, in one study, four of eight patients suffered significant clinical events, underscoring the need for long-term monitoring [<a href="#rid105">105</a>]. In a series involving 47 limbs in 27 patients with TAO, autologous bone marrow mononuclear cell (BM-MNC) implantation successfully prevented major limb amputation over a follow-up period of 12.0+8.6 years [<a href="#rid106">106</a>].<strong> </strong>BM-MNC implantation is clearly much more effective in treating critical limb ischemia secondary to TAO compared with treating patients with atherosclerotic peripheral artery disease [<a href="#rid77">77</a>].</p><p>Intramuscular injection of growth factors and gene transfer has also been tried. In a trial of six patients with nonhealing wounds (&gt;1 month), intramuscular vascular endothelial growth factor (VEGF) 165 was injected into seven affected limbs [<a href="#rid107">107</a>]. Ulcers completely healed in three of five limbs. In the other two patients, nocturnal rest pain was relieved, although both continued to have claudication. In all seven limbs, perfusion was improved on magnetic resonance imaging and newly visible collateral vessels were seen on contrast angiography. Another trial tested the safety of intramuscular gene transfer using naked plasmid DNA encoding the gene for VEGF in seven patients with TAO [<a href="#rid108">108</a>]. Ischemic pain in the affected limb was relieved or improved markedly in six of seven patients, and ischemic ulcers healed or improved in four of six patients.</p><p>Another therapy involves placing a Kirschner wire into the medullary canal of the tibia to stimulate angiogenesis. In a small study that treated 6 patients (11 extremities), rest pain was reduced, pain-free walking distance increased, and ulcer healing was reported [<a href="#rid109">109</a>]. However, in clinical practice, this technique is rarely, if ever, used. </p><p class="headingAnchor" id="H234644233"><span class="h1">INTERVENTION</span></p><p class="headingAnchor" id="H17"><span class="h2">Revascularization</span><span class="headingEndMark"> — </span>Revascularization is not usually feasible nor indicated because the disease is so distal, involving the small blood vessels of the hands, fingers, feet, and toes, and also because most patients with TAO do well with smoking cessation. If there is an anatomic option for endovascular therapy, it is worth pursuing [<a href="#rid110">110-115</a>]. Surgical revascularization is less feasible but may be indicated for those with superimposed peripheral artery disease. (See  <a class="medical medical_review" href="/d/html/8215.html" rel="external">"Management of chronic limb-threatening ischemia"</a>.) </p><p>Arterial bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Surgical bypass with autologous vein [<a href="#rid116">116-118</a>] or even omental graft may allow limb salvage [<a href="#rid119">119,120</a>]. Although long-term vein graft patency is less than that seen with atherosclerotic peripheral artery disease, limb salvage rates are reasonable and generally greater than 90 percent [<a href="#rid7">7,121</a>]. A possible explanation is that patent grafts, even over a short period of time, are sufficient to allow healing of ulcers in patients with TAO. Ulcers are not likely to develop or recur provided the patient is compliant with smoking cessation. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 71 bypasses performed on patients with TAO, primary and secondary patency rates were 50 and 63 percent at 5 years, and 43 and 56 percent at 10 years, respectively [<a href="#rid118">118</a>]. The 10 year patency rate of the nonsmoking group was significantly higher compared with the smoking group (67 versus 35 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, the overall limb salvage rate was 96 percent with 7 major and 36 minor amputations performed for the cohort (198 patients) [<a href="#rid122">122</a>]. Revascularization was performed in 19 patients, and the cumulative secondary patency rate was 58 percent at a mean of 5.4 years follow-up. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another small study of 27 patients with TAO who underwent revascularization, patency rates at 12, 24, and 36 months were 59, 48, and 33 percent, respectively [<a href="#rid7">7</a>]. However, the limb salvage rate was 93 percent. </p><p></p><p>Endovascular intervention including thrombolytic therapy or angioplasty has undergone limited investigation in patients with TAO [<a href="#rid114">114,123-128</a>]. Technical success rates range from 82 to 100 percent depending on the level of the lesion (higher for above the knee lesions). </p><p class="bulletIndent1"><span class="glyph">●</span>In a series 28 patients (32 limbs) undergoing endovascular procedures, 45 of 59 lesions below the knee were successfully treated, and only one major amputation occurred at 24 months follow-up [<a href="#rid125">125</a>]. The primary patency rate at 12, 24, and 36 months was 84, 78, and 75 percent, respectively; secondary patency was 87.5 percent at 12 and 24 months.<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 82 patients, 52 patients were randomized to endovascular therapy and 30 to medical therapy alone [<a href="#rid123">123</a>]. Healing of ischemic ulcers, amputation-free survival, and ankle-brachial index measurements were more improved in the endovascular group.<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 41 patients (45 limbs), clinical improvement occurred in 35 limbs (77.7 percent) over a mean follow-up of 29.8 months [<a href="#rid124">124</a>]. Amputation-free survival and limb salvage occurred in 93.3 percent at one and two years. Reintervention was required in 14 patients (45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review, the early and late outcomes of endovascular revascularization was reported [<a href="#rid128">128</a>]. The pooled technical success rate among 402 endovascular procedures was 86 percent, with no in-hospital mortality and an extremely low complication rate. The limb salvage rate was 94.1 percent at 12 months and 89.1 percent at 36 months.</p><p></p><p class="headingAnchor" id="H295029867"><span class="h2">Other interventions</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sympathectomy improves pain control in other vascular occlusive diseases [<a href="#rid18">18,129-131</a>]. Sympathectomy has been performed for TAO in the lower [<a href="#rid130">130,132,133</a>] and upper extremities [<a href="#rid134">134</a>]. Although sympathectomy anecdotally benefits some individuals, there are no data to guide patient selection. (See  <a class="medical medical_review" href="/d/html/15141.html" rel="external">"Overview of minimally invasive thoracic surgery", section on 'Sympathectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with other forms of chronic limb-threatening ischemia, spinal cord stimulation has also been used to manage pain in patients with TAO [<a href="#rid135">135-138</a>]. (See  <a class="medical medical_review" href="/d/html/94161.html" rel="external">"Investigational therapies for treating symptoms of lower extremity peripheral artery disease", section on 'Spinal cord stimulation'</a>.)</p><p></p><p class="headingAnchor" id="H87000741"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Several studies have evaluated long-term outcomes, including rates for major and minor amputations, and survival in patients with TAO [<a href="#rid15">15,16,81,86,96,127,139,140</a>]. An important limitation of virtually every outcome study of TAO has been the failure to objectively determine whether the patient actually stopped using tobacco or cannabis; smoking status is usually self-reported. </p><p>In a study of 110 patients with TAO, patients were followed from 1978 to 2001 [<a href="#rid86">86</a>]. Cumulative survival by Kaplan-Meier life table analysis was 84 percent up to 25 years after the initial consultation (mean duration of follow-up 10.6 years). The rate for any kind of amputation (upper or lower limb) was 43 percent with major amputations occurring in 12 percent. Forty-one patients who stopped smoking did not undergo major amputation; among the 69 patients who continued smoking, 19 percent required major amputation. No ischemic ulcers occurred or recurred in patients older than 60 years. </p><p>In another study that followed 111 patients with proven TAO for a mean of 15.6 years, the incidence of major amputation was 11 percent at 5 years, 21 percent at 10 years, and 23 percent at 20 years [<a href="#rid16">16</a>]. The risk of amputation in former smokers was eliminated by eight years after smoking cessation; the risk of amputation continued in patients who continued to smoke. This study was the only study that found reduced life expectancy in patients with TAO compared with the remainder of the population in the United States. The average age of death was 52 years. Older age at time of diagnosis was associated with an increased risk of death. </p><p>The largest outcome series included 224 patients meeting the criteria for the diagnosis of TAO [<a href="#rid81">81</a>]. Patients who stopped using tobacco had a significantly lower risk of amputation compared with those who continued to smoke. This study spanned 46 years (1970 to 2016) to achieve a sample size of 224 patients and underscores the difficulties in performing a prospective randomized trial in rare diseases such as TAO. It is important to recognize that while this is the largest outcomes series published, there are limitations to the data since patients may have been evaluated and treated differently over the nearly half-century time span of the study [<a href="#rid36">36</a>].</p><p>Outcomes were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The vascular event-free survival was 41 percent at 5 years, 23 percent at 10 years, and 19 percent at 15 years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total amputation-free survival was 85, 74, and 66 percent at 5, 10, and 15 years, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major amputation-free survival rates at 5, 10, and 15 years were 94, 91, and 91 percent, respectively. </p><p></p><p>In this study, multivariate analysis identified not being from a White population (hazard ratio [HR] 2.35, 95% CI 1.30-4.27) and limb infection (HR 12.1, 95% CI 3.5-42.1) as predictors of a poor outcome [<a href="#rid81">81</a>]. While the baseline differences between the two groups were not different, we have no information about the different socioeconomic factors that may have existed between the groups. There is the suggestion in some studies that the lower the socioeconomic status, the worse the prognosis in TAO [<a href="#rid86">86</a>]. Thus, it may not be related to race but to other factors such as living conditions, income, and overall socioeconomic status. While the amputation rate is lower in this study than in other studies, the authors acknowledge that this may be because of the difference in severity of disease at presentation as compared with other studies. Thirty percent of TAO patients had ischemic ulcers or necrosis at baseline, whereas this was observed in 45 to 80 percent of patients in other series. </p><p>On the other hand, another study reported a similar amputation rate with similar rates of ischemic ulceration and gangrene to the large study described above [<a href="#rid96">96</a>]. Thus, it appears that the milder the symptoms and signs at presentation, the lower the amputation rate. At first amputation, 5 (10.4 percent) of 48 patients stated they were not smoking, and at the next amputation 8 (23.5 percent) of 34 patients were not smoking. These amputation rates are high for patients who have stopped using tobacco or cannabis. On the other hand, why only 40 percent of patients who continue to smoke required an amputation and not more remains a question. Other factors may play a role in determining which patients are protected from amputation and which are more prone to amputation. In a French study, cannabis use was not independently associated with a worse prognosis as has been reported elsewhere [<a href="#rid141">141</a>]. In France, patients often mix cannabis with tobacco and hand roll their cigarettes. If this is the case, it would be very difficult to assess the role that cannabis played in vascular events and amputations in this series. </p><p class="headingAnchor" id="H234644142"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboangiitis obliterans</strong> – Thromboangiitis obliterans (TAO) is an inflammatory vascular disease of unclear etiology that affects medium and small arteries, veins, and nerves in the extremities, with rare involvement of visceral and cerebral vessels. Patients are predominantly young smokers who present with pain from distal extremity ischemia, ischemic digital ulcers, or digital gangrene. The disease is strongly associated with the use of tobacco products and also with cannabis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – TAO is characterized by segmental inflammatory thrombotic vessel occlusions. It is distinguished pathologically from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus but no fibrinoid necrosis and the presence of an intact internal elastic membrane. Although smoking is important to the pathogenesis, the specific etiologic mechanism remains unknown. Inflammatory, immunologic, and endothelial factors play a role. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and diagnosis</strong> – The evaluation of TAO consists of history and physical examination, vascular evaluation, and laboratory examination to serologically rule out other etiologies that can cause small and medium vessel occlusive arterial disease. (See <a class="local">'Clinical features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical diagnostic criteria</strong> – A clinical diagnosis without the need for biopsy can be established with the following commonly used criteria (see <a class="local">'Clinical criteria'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age less than 50 years (45 in some earlier series) (see <a class="local">'Epidemiology and risk factors'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Current or recent history of tobacco use (see <a class="local">'Risk factors'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Distal extremity ischemia (objectively noted on vascular testing) (see <a class="local">'Vascular testing'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Typical arteriographic findings of TAO (see <a class="local">'Vascular imaging'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (<a class="graphic graphic_table graphicRef68663" href="/d/graphic/68663.html" rel="external">table 1</a>) (see <a class="local">'Laboratory studies'</a> above and <a class="local">'Differential diagnosis'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vascular imaging</strong> – Imaging studies are not necessary to establish a clinical diagnosis but may be helpful in patients whose clinical features are not definitive. When imaging is performed, features suggestive of TAO include lack of atherosclerosis, no proximal source for embolism, the involvement of small and medium-sized vessels, segmental vascular occlusion, and collateralization around areas of occlusion (ie, corkscrew collaterals). However, such findings are nonspecific since they may be found in patients with other causes of small vessel occlusive disease. (See <a class="local">'Vascular imaging'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biopsy</strong> – Biopsy of a subcutaneous nodule or vein with superficial thrombophlebitis that shows typical acute phase changes on histology provides a definitive diagnosis, but biopsy is not usually needed. (See <a class="local">'Biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Smoking cessation</strong> – For patients who smoke, we recommend smoking cessation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). In addition to other demonstrated benefits, smoking cessation reduces symptoms and decreases the risk for major amputation. Continued smoking is associated with an overall amputation rate of 40 to 50 percent. (See <a class="local">'Smoking cessation'</a> above and <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vasodilators</strong> – For patients with ischemic pain, digit ulceration, or gangrene, intermittent pneumatic compression may improve pain by increasing blood flow. Calcium channel blockers may also help reduce vasospasm associated with Raynaud phenomenon. Other treatments that may be considered to manage pain include intravenous prostaglandin infusion, and possibly phosphodiesterase inhibitors. (See <a class="local">'Vasodilators'</a> above and <a class="local">'Intermittent pneumatic compression'</a> above and <a class="local">'Other interventions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of intervention</strong> – Revascularization is usually not indicated due to the distal nature of occlusive disease and because most patients do well with smoking cessation. However, there is a role for endovascular therapy in patients with TAO who are not responding to medical therapy alone. Bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Although the long-term patency rates are inferior to those seen with peripheral artery disease due to atherosclerosis, limb salvage rates are generally greater than 90 percent, but may be more correlated to smoking cessation. (See <a class="local">'Revascularization'</a> above.)</p><p></p><p class="headingAnchor" id="H2863160265"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Buerger L. Landmark publication from the American Journal of the Medical Sciences, 'Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene'. 1908. Am J Med Sci 2009; 337:274.</a></li><li><a class="nounderline abstract_t">Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010; 121:1858.</a></li><li><a class="nounderline abstract_t">Dargon PT, Landry GJ. Buerger's disease. Ann Vasc Surg 2012; 26:871.</a></li><li><a class="nounderline abstract_t">Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000; 343:864.</a></li><li><a class="nounderline abstract_t">Mills JL, Porter JM. Buerger's disease: a review and update. Semin Vasc Surg 1993; 6:14.</a></li><li><a class="nounderline abstract_t">Grove WJ, Stansby GP. Buerger's disease and cigarette smoking in Bangladesh. Ann R Coll Surg Engl 1992; 74:115.</a></li><li><a class="nounderline abstract_t">Dilege S, Aksoy M, Kayabali M, et al. Vascular reconstruction in Buerger's disease: is it feasible? Surg Today 2002; 32:1042.</a></li><li><a class="nounderline abstract_t">Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta Pathol Jpn 1989; 39:153.</a></li><li><a class="nounderline abstract_t">Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006; 1:14.</a></li><li><a class="nounderline abstract_t">Watanabe Y, Miyata T, Shigematsu K, et al. Current Trends in Epidemiology and Clinical Features of Thromboangiitis Obliterans in Japan　- A Nationwide Survey Using the Medical Support System Database. Circ J 2020; 84:1786.</a></li><li><a class="nounderline abstract_t">Choi B, Jang SY, Kim SK, et al. The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study. Cardiovasc Diagn Ther 2020; 10:1238.</a></li><li><a class="nounderline abstract_t">Lie JT. Thromboangiitis obliterans (Buerger's disease) in women. Medicine (Baltimore) 1987; 66:65.</a></li><li><a class="nounderline abstract_t">Elbadawi A, Sedhom R, Megaly M, et al. Estimate and Temporal Trends of Buerger Disease Hospitalizations in the United States. Am J Cardiol 2022; 169:158.</a></li><li><a class="nounderline abstract_t">Mills JL, Taylor LM Jr, Porter JM. Buerger's disease in the modern era. Am J Surg 1987; 154:123.</a></li><li><a class="nounderline abstract_t">Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82:IV3.</a></li><li><a class="nounderline abstract_t">Cooper LT, Tse TS, Mikhail MA, et al. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol 2004; 44:2410.</a></li><li><a class="nounderline abstract_t">Ehrenfeld M, Adar R. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). J Rheumatol 2000; 27:1818.</a></li><li><a class="nounderline abstract_t">Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg 1997; 67:264.</a></li><li><a class="nounderline abstract_t">Shionoya S, Ban I, Nakata Y, et al. Involvement of the iliac artery in Buerger's disease (pathogenesis and arterial reconstruction). J Cardiovasc Surg (Torino) 1978; 19:69.</a></li><li><a class="nounderline abstract_t">Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol 2000; 75 Suppl 1:S175.</a></li><li><a class="nounderline abstract_t">Soudet S, Le Joncour A, Quemeneur T, et al. Did the Clinical Spectrum of Thromboangiitis Obliterans Change in the Past 40 Years? Angiology 2020; 71:621.</a></li><li><a class="nounderline abstract_t">Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg 1991; 5:570.</a></li><li><a class="nounderline abstract_t">Papa M, Bass A, Adar R, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 1992; 111:527.</a></li><li><a class="nounderline abstract_t">Tavakoli H, Rezaii J, Esfandiari K, et al. Buerger's disease: a 10-year experience in Tehran, Iran. Clin Rheumatol 2008; 27:369.</a></li><li><a class="nounderline abstract_t">Martin-Blondel G, Koskas F, Cacoub P, Sène D. Is thromboangiitis obliterans presentation influenced by cannabis addiction? Ann Vasc Surg 2011; 25:469.</a></li><li><a class="nounderline abstract_t">Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 1988; 31:812.</a></li><li><a class="nounderline abstract_t">Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. Br J Dermatol 2005; 152:166.</a></li><li><a class="nounderline abstract_t">Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited--ten new case reports. Angiology 2001; 52:1.</a></li><li><a class="nounderline abstract_t">Cottencin O, Karila L, Lambert M, et al. Cannabis arteritis: review of the literature. J Addict Med 2010; 4:191.</a></li><li><a class="nounderline abstract_t">Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud syndrome with thromboangiitis obliterans--a meta-analysis. Angiology 2012; 63:315.</a></li><li><a class="nounderline abstract_t">Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42:107.</a></li><li><a class="nounderline abstract_t">Chen YW, Nagasawa T, Wara-Aswapati N, et al. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J Clin Periodontol 2009; 36:830.</a></li><li><a class="nounderline abstract_t">Lie JT. Thromboangiitis obliterans (Buerger's disease) revisited. Pathol Annu 1988; 23 Pt 2:257.</a></li><li><a class="nounderline abstract_t">Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am 1990; 16:269.</a></li><li><a class="nounderline abstract_t">Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis 2009; 206:328.</a></li><li><a class="nounderline abstract_t">Olin JW. Thromboangiitis Obliterans: 110 Years Old and Little Progress Made. J Am Heart Assoc 2018; 7:e011214.</a></li><li><a class="nounderline abstract_t">Leu HJ. Early inflammatory changes in thromboangiitis obliterans. Pathol Microbiol (Basel) 1975; 43:151.</a></li><li><a class="nounderline abstract_t">Joviliano EE, Dellalibera-Joviliano R, Dalio M, et al. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices. Int J Angiol 2009; 18:119.</a></li><li><a class="nounderline abstract_t">Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308:1113.</a></li><li><a class="nounderline abstract_t">Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 2003; 25:451.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Ito M, Nakagawa A, et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 1999; 29:451.</a></li><li><a class="nounderline abstract_t">Guzel E, Topal E, Yildirim A, et al. Targeting novel antigens in the arterial wall in thromboangiitis obliterans. Folia Histochem Cytobiol 2010; 48:134.</a></li><li><a class="nounderline abstract_t">Edo N, Miyai K, Ogata S, et al. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes. Cardiovasc Pathol 2010; 19:59.</a></li><li><a class="nounderline abstract_t">Dellalibera-Joviliano R, Joviliano EE, Silva JS, Evora PR. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol 2012; 170:28.</a></li><li><a class="nounderline abstract_t">Tamai H, Kobayashi M, Takeshita K, et al. Possible involvement of Notch signaling in the pathogenesis of Buerger's disease. Surg Today 2014; 44:307.</a></li><li><a class="nounderline abstract_t">Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998; 315:17.</a></li><li><a class="nounderline abstract_t">Azizi M, Boutouyrie P, Bura-Rivière A, et al. Thromboangiitis obliterans and endothelial function. Eur J Clin Invest 2010; 40:518.</a></li><li><a class="nounderline abstract_t">Joras M, Poredos P, Fras Z. Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation. Eur J Clin Invest 2006; 36:376.</a></li><li><a class="nounderline abstract_t">Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996; 94:II211.</a></li><li><a class="nounderline abstract_t">Narváez J, García-Gómez C, Álvarez L, et al. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore) 2016; 95:e5511.</a></li><li><a class="nounderline abstract_t">Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002; 7:259.</a></li><li><a class="nounderline abstract_t">Hus I, Sokolowska B, Walter-Croneck A, et al. Assessment of plasma prothrombotic factors in patients with Buerger's disease. Blood Coagul Fibrinolysis 2013; 24:133.</a></li><li><a class="nounderline abstract_t">Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007; 46:192.</a></li><li class="breakAll">Piazza G, Olin JW. Thrombangiitis Obliterans (Buerger’s Disease). In: Vascular Medicine, A Companion to Braunwald’s Heart Disease, 3rd edition (in press), Creager MA, Beckman J,  Loscalzo J (Eds), Saunders, Elsevier, Philadelphia 2018. p.568.</li><li><a class="nounderline abstract_t">Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18:18.</a></li><li><a class="nounderline abstract_t">Raimbeau A, Pistorius MA, Goueffic Y, et al. Digital ischaemia aetiologies and mid-term follow-up: A cohort study of 323 patients. Medicine (Baltimore) 2021; 100:e25659.</a></li><li><a class="nounderline abstract_t">Lee SA, Jeong MJ, Ko GY, et al. Long-term outcomes of large artery thromboangiitis obliterans and comparison with small artery thromboangiitis obliterans. Medicine (Baltimore) 2022; 101:e28512.</a></li><li><a class="nounderline abstract_t">Fujioka A, Yanishi K, Yukawa A, et al. A Multicenter Prospective Interventional Trial of Therapeutic Angiogenesis Using Bone Marrow-Derived Mononuclear Cell Implantation for Patients With Critical Limb-Threatening Ischemia Caused by Thromboangiitis Obliterans. Circ J 2023; 87:1229.</a></li><li><a class="nounderline abstract_t">Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. J Thorac Cardiovasc Surg 1997; 113:800.</a></li><li><a class="nounderline abstract_t">Lie JT. Visceral intestinal Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S249.</a></li><li><a class="nounderline abstract_t">Kurata A, Nonaka T, Arimura Y, et al. Multiple ulcers with perforation of the small intestine in buerger's disease: a case report. Gastroenterology 2003; 125:911.</a></li><li><a class="nounderline abstract_t">Cakmak A, Gyedu A, Akyol C, et al. Occlusion of the celiac trunk, the inferior mesenteric artery and stenosis of the superior mesenteric artery in peripheral thrombangiitis obliterans. Vasa 2009; 38:394.</a></li><li><a class="nounderline abstract_t">Michail PO, Filis KA, Delladetsima JK, et al. Thromboangiitis obliterans (Buerger's disease) in visceral vessels confirmed by angiographic and histological findings. Eur J Vasc Endovasc Surg 1998; 16:445.</a></li><li><a class="nounderline abstract_t">Tan G, Mintz AJ, Mintz B, et al. Peripheral vascular manifestation in patients receiving an amphetamine analog: A case series. Vasc Med 2019; 24:50.</a></li><li><a class="nounderline abstract_t">Pereira de Godoy JM, Braile DM. Buerger's disease and anticardiolipin antibodies. J Cardiovasc Med (Hagerstown) 2009; 10:792.</a></li><li><a class="nounderline abstract_t">Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996; 11:335.</a></li><li><a class="nounderline abstract_t">Vijayakumar A, Tiwari R, Kumar Prabhuswamy V. Thromboangiitis Obliterans (Buerger's Disease)-Current Practices. Int J Inflam 2013; 2013:156905.</a></li><li class="breakAll">Olin JW. Thromboangiitis obliterans (Buerger’s disease). In: Rutherford's Vascular surgery, 5th, Rutherford RB (Ed), WB Saunders, Philadelphia 2000. p.350.</li><li><a class="nounderline abstract_t">Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S243.</a></li><li><a class="nounderline abstract_t">Shionoya S. What is Buerger's disease? World J Surg 1983; 7:544.</a></li><li><a class="nounderline abstract_t">Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006; 5:89.</a></li><li><a class="nounderline abstract_t">Gerger H, Søgaard K, Macri EM, et al. Exposure to hand-arm vibrations in the workplace and the occurrence of hand-arm vibration syndrome, Dupuytren's contracture, and hypothenar hammer syndrome: a systematic review and meta-analysis. J Occup Environ Hyg 2023; 20:257.</a></li><li><a class="nounderline abstract_t">Dimmick SJ, Goh AC, Cauzza E, et al. Imaging appearances of Buerger's disease complications in the upper and lower limbs. Clin Radiol 2012; 67:1207.</a></li><li><a class="nounderline abstract_t">Lambeth JT, Yong NK. Arteriographic findings in thromboangiitis obliterans with emphasis on femoropopliteal involvement. Am J Roentgenol Radium Ther Nucl Med 1970; 109:553.</a></li><li><a class="nounderline abstract_t">Yoshimuta T, Akutsu K, Okajima T, et al. Corkscrew collaterals in Buerger's disease. Can J Cardiol 2009; 25:365.</a></li><li><a class="nounderline abstract_t">Fujii Y, Soga J, Hidaka T, et al. Color doppler flows of corkscrew collaterals in Thromboangiitis obliterans (Buerger's disease) using color duplex ultrasonography. J Am Coll Cardiol 2011; 57:2539.</a></li><li><a class="nounderline abstract_t">Nas OF, Kandemirli SG, Erdemli Gursel B, et al. Diagnostic utility of superb microvascular imaging in depiction of corkscrew collaterals in Buerger's disease. J Clin Ultrasound 2021; 49:129.</a></li><li><a class="nounderline abstract_t">Marder VJ, Mellinghoff IK. Cocaine and Buerger disease: is there a pathogenetic association? Arch Intern Med 2000; 160:2057.</a></li><li><a class="nounderline abstract_t">Noël B. Cocaine and arsenic-induced Raynaud's phenomenon. Clin Rheumatol 2002; 21:343.</a></li><li><a class="nounderline abstract_t">Cacione DG, Macedo CR, do Carmo Novaes F, Baptista-Silva JC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev 2020; 5:CD011033.</a></li><li><a class="nounderline abstract_t">Le Joncour A, Soudet S, Dupont A, et al. Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients. J Am Heart Assoc 2018; 7:e010677.</a></li><li><a class="nounderline abstract_t">Canter HI, Isci E, Erk Y. Vacuum-assisted wound closure for the management of a foot ulcer due to Buerger's disease. J Plast Reconstr Aesthet Surg 2009; 62:250.</a></li><li><a class="nounderline abstract_t">Gundogmus CA, Samadli V, Sorkun M, Oguzkurt L. The Effect of Smoking Cessation on the Technical Success of Endovascular Treatment for Thromboangiitis Obliterans. J Vasc Interv Radiol 2023; 34:1038.</a></li><li><a class="nounderline abstract_t">Hooten WM, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo Clin Proc 1998; 73:529.</a></li><li><a class="nounderline abstract_t">Hurt RD, Hays JT. Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans. Mayo Clin Proc 2008; 83:1187.</a></li><li><a class="nounderline abstract_t">Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39:176.</a></li><li><a class="nounderline abstract_t">Labropoulos N, Watson WC, Mansour MA, et al. Acute effects of intermittent pneumatic compression on popliteal artery blood flow. Arch Surg 1998; 133:1072.</a></li><li><a class="nounderline abstract_t">Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int Angiol 2002; 21:360.</a></li><li><a class="nounderline abstract_t">Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998; 15:300.</a></li><li><a class="nounderline abstract_t">Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990; 335:555.</a></li><li><a class="nounderline abstract_t">Bozkurt AK, Köksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006; 25:162.</a></li><li><a class="nounderline abstract_t">Cacione DG, Baptista-Silva JC, Macedo CR. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev 2016; 2:CD011033.</a></li><li><a class="nounderline abstract_t">Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35:48.</a></li><li><a class="nounderline abstract_t">Song F, Ji B, Chen T. Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans. Exp Ther Med 2018; 16:2349.</a></li><li><a class="nounderline abstract_t">Dean SM, Satiani B. Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 2001; 6:245.</a></li><li><a class="nounderline abstract_t">Fazeli B, Dadgar Moghadam M, Niroumand S. How to Treat a Patient with Thromboangiitis Obliterans: A Systematic Review. Ann Vasc Surg 2018; 49:219.</a></li><li><a class="nounderline abstract_t">Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209:10.</a></li><li><a class="nounderline abstract_t">De Haro J, Bleda S, Acin F. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease). Int J Cardiol 2014; 177:529.</a></li><li><a class="nounderline abstract_t">Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011; 4:15.</a></li><li><a class="nounderline abstract_t">Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156:1010.</a></li><li><a class="nounderline abstract_t">Motukuru V, Suresh KR, Vivekanand V, et al. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg 2008; 48:53S.</a></li><li><a class="nounderline abstract_t">Saito S, Nishikawa K, Obata H, Goto F. Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans. Angiology 2007; 58:429.</a></li><li><a class="nounderline abstract_t">Durdu S, Akar AR, Arat M, et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006; 44:732.</a></li><li><a class="nounderline abstract_t">Boda Z, Udvardy M, Rázsó K, et al. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger's disease. Clin Appl Thromb Hemost 2009; 15:552.</a></li><li><a class="nounderline abstract_t">Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006; 114:2679.</a></li><li><a class="nounderline abstract_t">Shibata R, Yamaguchi S, Murohara T. Therapeutic Angiogenesis Using Bone Marrow Mononuclear Cell Transplantation　- A New Standard Treatment for Thromboangiitis Obliterans? Circ J 2020; 84:549.</a></li><li><a class="nounderline abstract_t">Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28:964.</a></li><li><a class="nounderline abstract_t">Kim HJ, Jang SY, Park JI, et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36:336.</a></li><li><a class="nounderline abstract_t">Inan M, Alat I, Kutlu R, et al. Successful treatment of Buerger's Disease with intramedullary K-wire: the results of the first 11 extremities. Eur J Vasc Endovasc Surg 2005; 29:277.</a></li><li><a class="nounderline abstract_t">Kacmaz F, Kaya A, Keskin M, et al. Clinical outcomes of extended endovascular recanalization of 16 consecutive Buerger's disease patients. Vascular 2019; 27:233.</a></li><li><a class="nounderline abstract_t">Modaghegh MS, Hafezi S. Endovascular Treatment of Thromboangiitis Obliterans (Buerger's Disease). Vasc Endovascular Surg 2018; 52:124.</a></li><li><a class="nounderline abstract_t">Kawarada O, Kume T, Ayabe S, et al. Endovascular Therapy Outcomes and Intravascular Ultrasound Findings in Thromboangiitis Obliterans (Buerger's Disease). J Endovasc Ther 2017; 24:504.</a></li><li><a class="nounderline abstract_t">Lee JH, Ko YG, Choi D. Endovascular Treatment of Multilevel Chronic Total Occlusion Using a Stent Puncture Technique in Buerger's Disease. Korean Circ J 2016; 46:417.</a></li><li><a class="nounderline abstract_t">Graziani L, Morelli L, Parini F, et al. Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases. Ann Vasc Surg 2012; 26:387.</a></li><li><a class="nounderline abstract_t">Jun HJ. Endovascular Revascularization for the Obstruction after Patch Angioplasty in Buerger's Disease. Korean J Thorac Cardiovasc Surg 2014; 47:174.</a></li><li><a class="nounderline abstract_t">Lee T, Ra HD, Park YJ, et al. New routing alternative for proximal anterior tibial artery bypass in patients with Buerger disease. J Vasc Surg 2011; 54:1839.</a></li><li><a class="nounderline abstract_t">Sayin A, Bozkurt AK, Tüzün H, et al. Surgical treatment of Buerger's disease: experience with 216 patients. Cardiovasc Surg 1993; 1:377.</a></li><li><a class="nounderline abstract_t">Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13:186.</a></li><li><a class="nounderline abstract_t">Singh I, Ramteke VK. The role of omental transfer in Buerger's disease: New Delhi's experience. Aust N Z J Surg 1996; 66:372.</a></li><li><a class="nounderline abstract_t">Agarwal VK. Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger's disease) and retinal avascular diseases (retinitis pigmentosa). Int Surg 2007; 92:174.</a></li><li><a class="nounderline abstract_t">Nishikimi N. Fate of limbs with failed vascular reconstruction in Buerger's disease patients. Int J Cardiol 2000; 75 Suppl 1:S183.</a></li><li><a class="nounderline abstract_t">Bozkurt AK, Beşirli K, Köksal C, et al. Surgical treatment of Buerger's disease. Vascular 2004; 12:192.</a></li><li><a class="nounderline abstract_t">Soliman M, Mowafy K, Elsaadany NA, et al. Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study). SAGE Open Med 2020; 8:2050312120927636.</a></li><li><a class="nounderline abstract_t">Uyanık SA, Öğüşlü U, Aminu IS, et al. Endovascular Treatment of Critical Limb Ischemia in Buerger Disease (Thromboangiitis Obliterans) With Midterm Follow-Up: A Viable Option When Bypass Surgery Is Not Feasible. AJR Am J Roentgenol 2021; 216:421.</a></li><li><a class="nounderline abstract_t">Firat A, Igus B. Endovascular Recanalization of Thromboangiitis Obliterans (Buerger's Disease) in Twenty-Eight Consecutive Patients and Combined Antegrade-Retrograde Intervention in Eight Patients. Cardiovasc Intervent Radiol 2019; 42:820.</a></li><li><a class="nounderline abstract_t">Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 1993; 78:54.</a></li><li><a class="nounderline abstract_t">Ye K, Shi H, Qin J, et al. Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion. J Vasc Surg 2017; 66:1133.</a></li><li><a class="nounderline abstract_t">Galyfos G, Liakopoulos D, Chamzin A, et al. A systematic review and meta-analysis of early and late outcomes after endovascular angioplasty among patients with thromboangiitis obliterans and chronic limb ischemia. J Vasc Surg 2023; 77:1534.</a></li><li><a class="nounderline abstract_t">Hashmonai M, Cameron AE, Licht PB, et al. Thoracic sympathectomy: a review of current indications. Surg Endosc 2016; 30:1255.</a></li><li><a class="nounderline abstract_t">Talwar S, Prasad P. Single-stage lumbar sympathectomy and omentopexy: a new surgical approach towards patients with Buerger's disease. Trop Doct 2001; 31:73.</a></li><li><a class="nounderline abstract_t">Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol 2006; 111:147.</a></li><li><a class="nounderline abstract_t">Chander J, Singh L, Lal P, et al. Retroperitoneoscopic lumbar sympathectomy for buerger's disease: a novel technique. JSLS 2004; 8:291.</a></li><li><a class="nounderline abstract_t">Watarida S, Shiraishi S, Fujimura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. Surg Endosc 2002; 16:500.</a></li><li><a class="nounderline abstract_t">De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. Ann Thorac Surg 2002; 74:885.</a></li><li><a class="nounderline abstract_t">Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). J Vasc Surg 1999; 29:928.</a></li><li><a class="nounderline abstract_t">Chierichetti F, Mambrini S, Bagliani A, Odero A. Treatment of Buerger's disease with electrical spinal cord stimulation--review of three cases. Angiology 2002; 53:341.</a></li><li><a class="nounderline abstract_t">Pace AV, Saratzis N, Karokis D, et al. Spinal cord stimulation in Buerger's disease. Ann Rheum Dis 2002; 61:1114.</a></li><li><a class="nounderline abstract_t">Donas KP, Schulte S, Ktenidis K, Horsch S. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg 2005; 41:830.</a></li><li><a class="nounderline abstract_t">Kim DH, Ko YG, Ahn CM, et al. Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J Vasc Surg 2018; 67:1769.</a></li><li><a class="nounderline abstract_t">Fazeli B, Poredos P, Patel M, et al. Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. Int Angiol 2021; 40:395.</a></li><li><a class="nounderline abstract_t">Desbois AC, Cacoub P. Cannabis-associated arterial disease. Ann Vasc Surg 2013; 27:996.</a></li></ol></div><div id="topicVersionRevision">Topic 8205 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365174" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Landmark publication from the American Journal of the Medical Sciences, 'Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene'. 1908.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421527" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284771" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10995867" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252225" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Buerger's disease: a review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1567129" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Buerger's disease and cigarette smoking in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12541020" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vascular reconstruction in Buerger's disease: is it feasible?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2662703" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16722538" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32879220" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Current Trends in Epidemiology and Clinical Features of Thromboangiitis Obliterans in Japan　- A Nationwide Survey Using the Medical Support System Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33224747" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492659" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thromboangiitis obliterans (Buerger's disease) in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35168750" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Estimate and Temporal Trends of Buerger Disease Hospitalizations in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605510" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Buerger's disease in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2225420" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15607407" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914878" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9152156" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Buerger's disease in Hong Kong: a review of 89 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/627595" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Involvement of the iliac artery in Buerger's disease (pathogenesis and arterial reconstruction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980360" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Current status of thromboangiitis obliterans (Buerger's disease) in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32319306" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Did the Clinical Spectrum of Thromboangiitis Obliterans Change in the Past 40 Years?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1772769" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Buerger's disease (thromboangiitis obliterans).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1598672" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172574" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Buerger's disease: a 10-year experience in Tehran, Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549914" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is thromboangiitis obliterans presentation influenced by cannabis addiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3382454" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656820" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cannabis arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11205926" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cannabis arteritis revisited--ten new case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21769037" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cannabis arteritis: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733945" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The association of Raynaud syndrome with thromboangiitis obliterans--a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012459" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Oral bacteria in the occluded arteries of patients with Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19678860" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association between periodontitis and anti-cardiolipin antibodies in Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3060814" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thromboangiitis obliterans (Buerger's disease) revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1971725" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19269635" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thromboangiitis obliterans in the 21st century--a new face of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571606" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thromboangiitis Obliterans: 110 Years Old and Little Progress Made.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1228574" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Early inflammatory changes in thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22477511" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835334" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cellular sensitivity to collagen in thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12713785" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunobiologic analysis of arterial tissue in Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069909" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20529829" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Targeting novel antigens in the arterial wall in thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135391" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22943198" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23605216" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Possible involvement of Notch signaling in the pathogenesis of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427570" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antiendothelial cell antibodies in thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584171" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thromboangiitis obliterans and endothelial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16684120" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901748" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902617" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12710840" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antiphospholipid antibodies in thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358197" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Assessment of plasma prothrombotic factors in patients with Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116654" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116654" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344615" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011027" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Digital ischaemia aetiologies and mid-term follow-up: A cohort study of 323 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35029910" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term outcomes of large artery thromboangiitis obliterans and comparison with small artery thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36908168" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Multicenter Prospective Interventional Trial of Therapeutic Angiogenesis Using Bone Marrow-Derived Mononuclear Cell Implantation for Patients With Critical Limb-Threatening Ischemia Caused by Thromboangiitis Obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104994" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9951827" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Visceral intestinal Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12949735" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Multiple ulcers with perforation of the small intestine in buerger's disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19998262" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Occlusion of the celiac trunk, the inferior mesenteric artery and stenosis of the superior mesenteric artery in peripheral thrombangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854560" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thromboangiitis obliterans (Buerger's disease) in visceral vessels confirmed by angiographic and histological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30105937" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Peripheral vascular manifestation in patients receiving an amphetamine analog: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455050" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Buerger's disease and anticardiolipin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8601245" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A point scoring system for the clinical diagnosis of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102033" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102033" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9951826" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnostic criteria of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6624130" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : What is Buerger's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698911" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnostic criteria and treatment of Buerger's disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37000463" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Exposure to hand-arm vibrations in the workplace and the occurrence of hand-arm vibration syndrome, Dupuytren's contracture, and hypothenar hammer syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784658" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Imaging appearances of Buerger's disease complications in the upper and lower limbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5431503" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Arteriographic findings in thromboangiitis obliterans with emphasis on femoropopliteal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19536378" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Corkscrew collaterals in Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679855" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Color doppler flows of corkscrew collaterals in Thromboangiitis obliterans (Buerger's disease) using color duplex ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32557645" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diagnostic utility of superb microvascular imaging in depiction of corkscrew collaterals in Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888980" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cocaine and Buerger disease: is there a pathogenetic association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12296288" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cocaine and arsenic-induced Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364620" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pharmacological treatment for Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571594" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980686" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vacuum-assisted wound closure for the management of a foot ulcer due to Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36791958" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The Effect of Smoking Cessation on the Technical Success of Endovascular Treatment for Thromboangiitis Obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9621859" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18828981" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718836" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical and social consequences of Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790203" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Acute effects of intermittent pneumatic compression on popliteal artery blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12518117" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610341" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689791" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763533" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26828199" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pharmacological treatment for Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197586" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cilostazol: treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30186478" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11958391" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Three cases of digital ischemia successfully treated with cilostazol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29421414" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : How to Treat a Patient with Thromboangiitis Obliterans: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740466" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217217" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205941" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061721" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19084740" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652224" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926085" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818231" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145986" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32173685" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Therapeutic Angiogenesis Using Bone Marrow Mononuclear Cell Transplantation　- A New Standard Treatment for Thromboangiitis Obliterans?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845647" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365252" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15694801" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Successful treatment of Buerger's Disease with intramedullary K-wire: the results of the first 11 extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305010" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinical outcomes of extended endovascular recanalization of 16 consecutive Buerger's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29237360" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Endovascular Treatment of Thromboangiitis Obliterans (Buerger's Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743226" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Endovascular Therapy Outcomes and Intravascular Ultrasound Findings in Thromboangiitis Obliterans (Buerger's Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27275180" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Endovascular Treatment of Multilevel Chronic Total Occlusion Using a Stent Puncture Technique in Buerger's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285343" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24782974" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Endovascular Revascularization for the Obstruction after Patch Angioplasty in Buerger's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21944922" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : New routing alternative for proximal anterior tibial artery bypass in patients with Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076063" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Surgical treatment of Buerger's disease: experience with 216 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091153" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678856" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The role of omental transfer in Buerger's disease: New Delhi's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972474" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger's disease) and retinal avascular diseases (retinitis pigmentosa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980361" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Fate of limbs with failed vascular reconstruction in Buerger's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15586528" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Surgical treatment of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32551111" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33325735" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Endovascular Treatment of Critical Limb Ischemia in Buerger Disease (Thromboangiitis Obliterans) With Midterm Follow-Up: A Viable Option When Bypass Surgery Is Not Feasible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30834476" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Endovascular Recanalization of Thromboangiitis Obliterans (Buerger's Disease) in Twenty-Eight Consecutive Patients and Combined Antegrade-Retrograde Intervention in Eight Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473086" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697938" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36174815" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A systematic review and meta-analysis of early and late outcomes after endovascular angioplasty among patients with thromboangiitis obliterans and chronic limb ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123342" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Thoracic sympathectomy: a review of current indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11321275" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Single-stage lumbar sympathectomy and omentopexy: a new surgical approach towards patients with Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580754" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347122" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Retroperitoneoscopic lumbar sympathectomy for buerger's disease: a novel technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11928036" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Laparoscopic lumbar sympathectomy for lower-limb disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12238855" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231644" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12025923" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Treatment of Buerger's disease with electrical spinal cord stimulation--review of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429549" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Spinal cord stimulation in Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886668" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : The role of epidural spinal cord stimulation in the treatment of Buerger's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157680" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34236154" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23850313" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Cannabis-associated arterial disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
